A Prospective Analysis of Vasoreactivity and Mortality in WHO Group 3 Pulmonary Hypertension
ABSTRACT Prognostic markers of Group 3 pulmonary hypertension (PH) remain largely unknown. In this study, we evaluate clinical data to provide a comprehensive profile of patients with Group 3 PH and evaluate the potential use of vasoreactivity testing as a prognostic tool within this population. We...
Saved in:
Main Authors: | Daniel J. Strick, Carl Tanba, Meredith A. Kaplan, Nicholas S. Hill, Harrison W. Farber, David Condon, Ioana R. Preston |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-04-01
|
Series: | Pulmonary Circulation |
Subjects: | |
Online Access: | https://doi.org/10.1002/pul2.70078 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease
by: A. A. Shmalts, et al.
Published: (2022-10-01) -
Analysis of exhaled nitric oxide and its influencing factors in patients with chronic obstructive pulmonary disease
by: Ya Shen, et al.
Published: (2025-07-01) -
Level 3 Cardiopulmonary Exercise Testing to Guide Therapeutic Decisions in Non-Severe Pulmonary Hypertension with Lung Disease
by: Raj Parikh, et al.
Published: (2025-07-01) -
Inhaled nitric oxide: are expectations justified?
by: I. A. Kozlov
Published: (2024-12-01) -
INHALED NITRIC OXIDE: CLINICAL EFFECTS AND INFLUENCE ON THE PROFILE OF INFLAMMATORY MARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)